Aurora Kinase a Phosphorylates BRCA2 to Promote Cell Sensitivity to PARP Inhibition

Hui Li,Yang Shao,Shuoer Wang,Yinjue Yu,Lina Yang,Jiao Meng,Chaosu Hu,Chunxia Ren,Gong Yang

DOI: https://doi.org/10.2139/ssrn.4163700

2022-01-01

Abstract:Background: BRCA2-deficiency may confer cancer cells sensitivity to PARP inhibitors (PARPi) because of the compromised DNA homologous recombination (HR) repair. We previously reported AURKA suppressed BRCA2 expression to control HR. However, the exact mechanism is unclear.Methods: In vitro kinase assays and mass spectrometry were used to examine the phosphorylation of BRCA2 by AURKA. In vitro and in vivo experiments were performed to test the phosphorylation, polyubiquitination and tumorigenesis of wild-type or mutant BRCA2 stably expressing cells. Immunohistochemistry was used to determine the expression levels of p-BRCA2, BRCA2 and AURKA in ovarian cancer tissues.Finding: Using in vitro kinase assay and mass spectrum analysis, we show phosphorylation of BRCA2 at threonine 10 (T10) by AURKA promotes the interaction between BRCA2 and Skp2, which subsequently induces BRCA2 instability and nuclear ubiquitin-proteasome degradation, whereas the BRCA2-T10A mutant is unphosphorylated by AURKA, neither degraded by Skp2, but stabilized in nucleus. The non-degradable BRCA2-T10A enhances HR capacity via activation of ATM/Chk2 signaling to induce PARPi resistance. Moreover, SNP rs28897701 (A75P) and rs572782576 (L86P) mutants in BRCA2 interrupt phosphorylation of BRCA2 at T10 by AURKA and consequently induce PARPi resistance. Clinically, AURKA is positively correlated with cytoplasmic pBRCA2 (T10), but negatively correlated with nuclear BRCA2 in ovarian cancer.Interpretation: These data highlight phosphorylation of BRCA2 at T10 by AURKA may be a key event to mediate nuclear degradation and dysfunction of BRCA2, indicating a promising treatment strategy for ovarian cancer or other cancer types with PARPi.Funding Information: This work was supported by grants from the National Natural Science Foundation of China (81372797, 82002726, 81572553, 81772789 and 81402153) and the Clinical Postdoctoral Program of Physician Excellence (ZYJH202103).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: Research involved animal experiments was reviewed and approved by Fudan University Institutional Animal Care and Use Committee (2020 wuyuan JS-047). The implementation complies with the“International Ethical Standards Concerning Human 21 Research” stated in the “Helsinki Declaration”.